clear cell carcinoma of ovary
Conditions
Sponsors
Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Advanced ovarian clear cell carcinoma patient satisfying the following conditions, 1 Diagnosed as clear cell carcinoma of ovary 2 age 20 to 80 years old 3ECOG performance status of 0 to 1 4 HLA-A24 or A2 5Meet the following criteria for organ functions WBC more than 3000/mm3 Hemoglobin more than 8.0g/dl platelet more than 50000/mm3 serum bililnin less than 3.0mg/dl serum AST/ALT less than 200U/l serum creatinine less than 1.5mg/dl 6 survival period is expected to be more than 3 months 7Written informed consent has been obtained 8At least 4 weeks since last therapy for ovarin cancer
Exclusion criteria
Exclusion criteria: 1 Uncontrolled pleural effusion or ascites 2 There are other malignancies. 3 Active infection excluding HBV,HCV 4 Positive for HIV 5clinically significant heart disease angina within the past six months, or uncontrolled Diabetes Mellitus 6There is severe psychiatric disorder 7Pregnant or lactaing woman,who are willing to be pregnant 8Past history of severe drug allergy 9Immunodeficiency, previous splenectomy,irradiation to the spleen 10Ongoing treatment with corticosteroid or immnosuppresant drug 11Previous allogrant transplantation 12 Responsible doctors juged the patient in appropriate for the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The one-year and two-year recurrence rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects of GPC3 vaccination. GPC3-specific immune-responses to GPC3 vaccination | — |
Countries
Japan
Contacts
Public ContactKiyosumi Shibata
Nagoya University Graduate School of Medicine Department of Obstetrics and Gynecology
Outcome results
None listed